欢迎访问药物流行病学杂志网站！

设为首页加入收藏

国家科技部中国科技论文统计源期刊

中国科技核心期刊

WHO西太平洋地区医学索引(WPRIM)收录期刊

湖北优秀期刊

《药物流行病学杂志》官方网站与投审稿系统变更通知<点击查看详情>

左卡尼汀联合曲美他嗪治疗老年缺血性心肌病心力衰竭短期疗效观察

Short term Efficacy of Levocarnitine Combined with Trimetazidine in Elderly Heart Failure of Ischemic Cardiomyopathy

投稿时间：2014-08-28 修订日期：2015-01-21

DOI：

中文关键词: 左卡尼汀曲美他嗪老年缺血性心肌病心力衰竭

英文关键词:Levocarnitine Trimetazidine Elderly heart failure of ischemic cardiomyopathy

基金项目:

作者	单位
李幸苗	永康市第一人民医院浙江永康 321300；
吕向群	永康市第一人民医院
应志强	浙江大学医学院附属第二医院

摘要点击次数: 986

全文下载次数: 0

中文摘要:

摘要目的： 观察左卡尼汀联合曲美他嗪治疗老年缺血性心肌病心力衰竭的短期疗效与安全性。方法: 106例老年缺血性心肌病心力衰竭患者按入院先后顺序分为观察组和对照组各53例。两组患者均施行抗血小板、抗心肌缺血、调脂等基础治疗，对照组在此基础上加用曲美他嗪20 mg，po，tid，观察组在对照组基础上再加用左卡尼汀2 g+0.9%氯化钠注射液100 ml，ivd，qd。治疗4周后，比较两组患者治疗前后的心功能改善效果，心功能指标(LVEDD、LVESD、LVEF)以及心肌缺血标志物（CKMB、cTn I及BNP）水平变化，以及药品不良反应发生率、再住院率与病死率。结果:观察组显效率与总有效率均明显高于对照组（P<0.05或0.000 1）。治疗后，两组的LVEDD、LVESD均较前明显下降，LVEF较前明显上升（P<0.05），且观察组的LVEDD与LVESD明显低于对照组，LVEF则高于对照组（P<0.05或0.000 1）。治疗后，两组CKMB、TNI及BNP的含量均明显低于治疗前（P<0.05），且观察组的CKMB、TNI及BNP的含量均低于对照组（P<0.05）。两组患者药品不良反应发生率、再住院率与病死率比较，差异无统计学意义（P>0.05）。结论: 常规治疗基础上加用左卡尼汀联合曲美他嗪治疗老年缺血性心肌病心力衰竭，可显著改善患者心功能，临床效果更优，值得推广。

英文摘要:

ABSTRACT Objective: To observe and study the short term efficacy of levocarnitine combined with trimetazidine in the treatment of elderly heart failure of ischemic cardiomyopathy. Methods: Totally 106 elderly patients with ischemic cardiomyopathy and heart failure were randomly divided into the observation group and the control group with 53 ones in each. All the patients were given anti platelet, anti myocardial ischemia and lipid lowering therapy as well as the conventional therapy on myocardial ischemia. The control group was treated with trimetazidine, 20mg，po，tid, while the observation group was additionally treated with 2g levocarnitine with 0.9% sodium chloride injections, 100ml，ivd，qd. The treatment course was 4 weeks. The improvement of heart function and the changes in cardiac function indices (including LVEDD, LVESD and LVEF) and cardiac ischemia markers (CKMB, TNI and BNP) before and after the treatment were compared between the two groups. The incidence of adverse drug reactions, the rate of re hospitalization and mortality in the two groups were also compared.Results: The significant efficiency and total effective rate in the observation group were much higher than those in the control group （P<0.05 or 0.000 1）. After the treatment, LVEDD and LVESD in the two groups were declined, LVEF was increased (P<0.05), and the changes in the observation group were more notable than those in the control group （P<0.05 or 0.000 1）. After the treatment, the contents of CKMB, TNI and BNP in the two groups were lower than those before the treatment （P<0.05）, and the decrease in the observation group was more notable than that in the control group（P<0.05）. There were no significant differences in the incidence of adverse reactions, re admission rate and mortality between the two groups (P>0.05). Conclusion:Levocarnitine combined with trimetazidine on the basis of the conditional therapy in the treatment of elderly patients with ischemic cardiomyopathy and heart failure can effectively improve heart function with better clinical efficacy, which is worthy of promotion in clinic.

查看全文查看/发表评论下载PDF阅读器

关闭